Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation : Opportunities and Challenges of Real-World Evidence

Show full item record



Permalink

http://hdl.handle.net/10138/346519

Citation

Helanterä , I , Snyder , J , asberg , A , Cruzado , J M , Bell , S , Legendre , C , Tedesco-Silva , H , Barcelos , G T , Geissbuehler , Y , Prieto , L , Christian , J B , Scalfaro , E & Dreyer , N A 2022 , ' Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation : Opportunities and Challenges of Real-World Evidence ' , Transplant International , vol. 35 , 10329 . https://doi.org/10.3389/ti.2022.10329

Title: Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation : Opportunities and Challenges of Real-World Evidence
Author: Helanterä, Ilkka; Snyder, Jon; asberg, Anders; Cruzado, Josep Maria; Bell, Samira; Legendre, Christophe; Tedesco-Silva, Helio; Barcelos, Giovanna Tedesco; Geissbuehler, Yvonne; Prieto, Luis; Christian, Jennifer B.; Scalfaro, Erik; Dreyer, Nancy A.
Contributor organization: HUS Abdominal Center
IV kirurgian klinikka
Date: 2022-05-03
Language: eng
Number of pages: 8
Belongs to series: Transplant International
ISSN: 0934-0874
DOI: https://doi.org/10.3389/ti.2022.10329
URI: http://hdl.handle.net/10138/346519
Abstract: While great progress has been made in transplantation medicine, long-term graft failure and serious side effects still pose a challenge in kidney transplantation. Effective and safe long-term treatments are needed. Therefore, evidence of the lasting benefit-risk of novel therapies is required. Demonstrating superiority of novel therapies is unlikely via conventional randomized controlled trials, as long-term follow-up in large sample sizes pose statistical and operational challenges. Furthermore, endpoints generally accepted in short-term clinical trials need to be translated to real-world (RW) care settings, enabling robust assessments of novel treatments. Hence, there is an evidence gap that calls for innovative clinical trial designs, with RW evidence (RWE) providing an opportunity to facilitate longitudinal transplant research with timely translation to clinical practice. Nonetheless, the current RWE landscape shows considerable heterogeneity, with few registries capturing detailed data to support the establishment of new endpoints. The main recommendations by leading scientists in the field are increased collaboration between registries for data harmonization and leveraging the development of technology innovations for data sharing under high privacy standards. This will aid the development of clinically meaningful endpoints and data models, enabling future long-term research and ultimately establish optimal long-term outcomes for transplant patients.
Subject: data harmonization
extension studies
real-world evidence
registries
kidney transplantation
END-POINTS
FOLLOW-UP
RECIPIENTS
IMMUNOSUPPRESSION
INTERVENTIONS
CHECKLIST
CONSENSUS
OUTCOMES
TRIALS
3126 Surgery, anesthesiology, intensive care, radiology
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
ti_35_10329.pdf 1.171Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record